ANXA2 and obesity disorder: Since prohibitin and ANX2 were identified as surface markers of AdECs useful for its targeting with a peptide precision therapy [98,99], accumulating evidence suggests that the potential of prohibitin or ANX2 as a therapeutic agent against obesity.